✦ LIBER ✦

Prolonged Paradoxical Reaction of Tuberculosis in an HIV-Infected Patient after Initiation of Highly Active Antiretroviral Therapy

✍ Scribed by A. Ramos; A. Asensio; I. Perales; M. C. Montero; T. Martín

Publisher: Springer
Year: 2003
Tongue: English
Weight: 129 KB
Volume: 22
Category: Article
ISSN: 0934-9723
DOI: 10.1007/s10096-003-0940-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Reduction of Immune System Activation in

Reduction of Immune System Activation in HIV-1-Infected Patients Undergoing Highly Active Antiretroviral Therapy

✍ J. M. Franco; A. Rubio; C. Rey; M. Leal; J. Macías; J. A. Pineda; B. Sánchez; A. 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 67 KB

Skin-Related Quality of Life in HIV-infe

✍ Paradi Mirmirani; Toby A. Maurer; Timothy G. Berger; Laura P. Sands; Mary-Margar 📂 Article 📅 2002 🏛 Springer-Verlag 🌐 English ⚖ 191 KB

Impact of Highly Active Antiretroviral T

Impact of Highly Active Antiretroviral Therapy on Fever of Unknown Origin in HIV-Infected Patients

✍ F. Lozano; J. Torre-Cisneros; J. Santos; E. León; A. Domínguez; M. Montesdeoca; 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 19 KB

Decline of a visceral leishmaniasis epid

Decline of a visceral leishmaniasis epidemic in HIV-infected patients after the introduction of highly active antiretroviral therapy (HAART)

✍ R. López-Vélez; J. L. Casado; V. Pintado 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB

Persistent parvovirus B19 related anemia

Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: Complete remission associated with highly active antiretroviral therapy

✍ Mylonakis, Eleftherios; Dickinson, Brian P.; Mileno, Maria D.; Flanigan, Timothy 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 34 KB 👁 2 views

A human immunodeficiency virus (HIV)-infected individual was first diagnosed with red blood cell aplasia due to B19 parvovirus infection in late 1989. Over the subsequent seven-year period, he received a total of 119 units of red blood cells (RBCs) and intravenous immunoglobulin every 2-3 weeks. In

Soluble urokinase plasminogen activator

Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy

✍ Ove Andersen; Jesper Eugen-Olsen; Kristian Kofoed; Johan Iversen; Steen B. Hauga 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 224 KB

## Abstract Circulating soluble urokinase plasminogen activator receptor (suPAR) reflects the immune and pro‐inflammatory status of the HIV‐infected patient. Highly active antiretroviral therapy (HAART) suppresses suPAR. Independent of the immune response to HAART, suPAR remains elevated in some HI